Physician profile
Gerald A Turner
NPI 1285630715
$5,350.58
in general payments reported to CMS, 2019-2025
28 companies · $1,531 in 2025
The $1,531 reported for 2025 was more than what 92% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $591 · 2020: $556 · 2021: $410 · 2022: $417 · 2023: $560 · 2024: $1,286 · 2025: $1,531.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,376.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,376.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,400.40 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $790.81 | 2019-2025 | Rybelsus, Ozempic |
| Lilly USA, LLC | $676.19 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $532.20 | 2021-2025 | Ubrelvy, Qulipta |
| Bayer Healthcare Pharmaceuticals INC. | $277.95 | 2021-2025 | |
| Qol Medical, LLC | $183.73 | 2024-2025 | Sucraid, Sucraid |
| Takeda Pharmaceuticals U.S.A., INC. | $178.93 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $150.36 | 2019-2025 | Jardiance, Ofev |
| Merck Sharp & Dohme LLC | $145.20 | 2019-2021 | |
| Amgen INC. | $139.91 | 2019-2025 | Repatha, Otezla, Evenity |
| Teva Pharmaceuticals USA, INC. | $126.15 | 2019-2020 | |
| Lundbeck LLC | $121.87 | 2025 | Rexulti |
| Exact Sciences Corporation | $87.91 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Pfizer INC. | $83.92 | 2019-2025 | |
| Shield Therapeutics INC | $66.25 | 2023-2024 | Accrufer |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $64.18 | 2023 | Trelegy Ellipta, Arexvy |
| Esperion Therapeutics, INC. | $59.65 | 2024-2025 | Nexletol |
| Otsuka America Pharmaceutical, INC. | $53.82 | 2025 | Rexulti |
| Sanofi-Aventis U.S. LLC | $45.34 | 2019-2020 | |
| Axsome Therapeutics, INC. | $31.22 | 2025 | Auvelity |
| Janssen Pharmaceuticals, INC | $31.05 | 2020-2022 | |
| Phathom Pharmaceuticals, INC. | $17.29 | 2024 | Voquezna |
| Vertex Pharmaceuticals Incorporated | $16.81 | 2025 | |
| Boston Scientific Corporation | $14.37 | 2022 | |
| Daiichi Sankyo INC. | $14.37 | 2021 | |
| Genentech USA, INC. | $13.94 | 2020 | |
| Idorsia Pharmaceuticals US INC | $13.49 | 2022 | |
| Shire North American Group INC | $13.27 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gerald Turner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.